Continuing (maintenance) therapy in lymphoblastic leukaemia: Lessons from MRC UKALL X

British Journal of Haematology

Volumn 98, Issue 4, 1997, Pages 945-951

  Chessells, J M ^a   Harrison, G ^b   Lilleyman, J S ^c   Bailey, C C ^d   Richards, S M ^b  

^a UNIVERSITY COLLEGE LONDON   (United Kingdom)

^b RADCLIFFE INFIRMARY   (United Kingdom)

^c ST BARTHOLOMEW S HOSPITAL   (United Kingdom)

^d Northern and Yorkshire Region   (United Kingdom)

Author keywords

Childhood lymphoblastic leukaemia; Maintenance therapy; Mercaptopurine; Methotrexate

Indexed keywords

ASPARAGINASE; COTRIMOXAZOLE; MERCAPTOPURINE; METHOTREXATE; PREDNISOLONE;

ACUTE LYMPHOBLASTIC LEUKEMIA; ADOLESCENT; ARTICLE; BONE MARROW SUPPRESSION; CANCER RADIOTHERAPY; CHILD; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DOSE TIME EFFECT RELATION; DRUG EFFICACY; FEMALE; HUMAN; INFANT; INTRATHECAL DRUG ADMINISTRATION; LEUKEMIA REMISSION; LEUKOCYTE COUNT; MAJOR CLINICAL STUDY; MALE; NEUTROPENIA; ORAL DRUG ADMINISTRATION; PRESCHOOL CHILD; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; SCHOOL CHILD;

EID: 0030825783     PISSN: 00071048     EISSN: None     Source Type: Journal    
DOI: 10.1046/j.1365-2141.1997.3113127.x     Document Type: Article

References (19)

1. Chessells, J.M. (1992) Treatment of childhood acute lymphoblastic leukaemia: present issues and future prospects. Blood Reviews, 6, 193-203.
2. Chessells, J.M., Bailey, C. & Richards, S.M. (1995a) Intensification of treatment and survival in all children with lymphoblastic leukaemia: results of UK Medical Research Council trial UKALL X. Lancet, 345, 143-148.
3. Chessells, J.M., Durrant, J., Hardisty, R.M. & Richards, S. (1986) Medical Research Council UKALL V: an attempt to reduce the immunosuppressive effects of therapy in childhood acute lymphoblastic leukaemia. Journal of Clinical Oncology, 4, 1758-1764.
4. Chessells, J.M., Richards, S.M., Bailey, C.C., Lilleyman, J.S. & Eden, O.B. (1995b) Gender and treatment outcome in childhood lymphoblastic leukaemia: report from the MRC UKALL Trials. British Journal of Haematology, 89, 364-372.
5. Childhood ALL Collaborative Group (1996) Duration and intensity of maintenance chemotherapy in acute lymphoblastic leukaemia: overview of 42 trials involving 12000 randomized children. Lancet, 347, 1783-1788.
6. Davies, H.A., Lennard, L. & Lilleyman, J.S. (1993) Variable mercaptopurine metabolism in children with leukaemia: a problem of non-compliance? British Medical Journal, 306, 1239-1240.
7. Dibenedetto, S.P., Guardabasso, V., Ragusa, R., Cataldo, A.D., Miraglia, V., D'Amico, S. & Ippolito, A.M. (1994) 6-Mercaptopurine cumulative dose: a critical factor of maintenance therapy in average risk childhood acute lymphoblastic leukemia. Pediatric Hematology and Oncology, 11, 251-258.
8. Dolan, G., Lilleyman, J.S. & Richards, S.M. (1989) Prognostic importance of myelosuppression during maintenance treatment of lymphoblastic leukaemia. Archives of Disease in Childhood, 64, 1231-1234.
9. Eden, O.B., Lilleyman, J.S., Richards, S., Shaw, M.P. & Peto, J. (1991) Results of Medical Research Council Childhood Leukaemia Trial UKALL VIII (Report to the Medical Research Council on behalf of the Working Party on Leukaemia in Childhood). British Journal of Haematology, 78, 187-196.
10. Gale, R.P. & Butturini, A. (1991) Maintenance chemotherapy and cure of childhood acute lymphoblastic leukaemia. Lancet, 338, 1315-1318.
11. Hale, J.P. & Lilleyman, J.S. (1991) Importance of 6-mercaptopurine dose in lymphoblastic leukaemia. Archives of Diseases of Children, 66, 462-466.
12. Henze, G., Fengler, R., Reiter, A., Ritter, J. & Riehm, H. (1990) Impact of early intensive reinduction therapy on event-free survival in children with low-risk acute lymphoblastic leukemia. Haematology and Blood Transfusion, 33, 483-488.
13. Lennard, L. & Lilleyman, J.S. (1989) Variable mercaptopurine metabolism and treatment outcome in childhood lymphoblastic leukemia. Journal of Clinical Oncology, 7, 1816-1823.
14. Lilleyman, J.S. & Lennard, L. (1996) Non-compliance with oral chemotherapy in childhood leukaemia. British Medical Journal, 313, 1219-1220.
15. Nesbit, M.E.J., Sather, H.N., Robison, L.L., Ortega, J.A., Hammond, D.G., and Childrens Cancer Study Group (1983) Randomised study of 3 years versus 5 years of chemotherapy in childhood acute lymphoblastic leukaemia. Journal of Clinical Oncology, 1, 308-316.
16. Pearson, A.D.J., Amineddine, H.A., Yule, M., Mills, S., Long, D.R., Craft, A.W. & Chessells, J.M. (1991) The influence of serum methotrexate concentrations and drug dosage on outcome in childhood acute lymphoblastic leukaemia. British Journal of Cancer, 64, 169-173.
17. Peto, R., Pike, M.C., Armitage, P., Breslow, N.E., Cox, D.R., Howard, S.V., Mantel, N., McPherson, K., Peto, J. & Smith, P.G. (1977) Design and analysis of randomized clinical trials requiring prolonged observation of each patient. II. Analysis and examples. British Journal of Cancer, 35, 1-39.
18. Pinkel, D., Hernandez, K., Borella, L., Holton, C., Aur, R., Samoy, G. & Pratt, C. (1971) Drug dosage and remission duration in childhood lymphocytic leukemia. Cancer, 27, 247-256.
19. Schmiegelow, K., Schroder, H., Gustafsson, G., Kristinsson, J., Glomstein, A., Salmi, T. & Wranne, L. (1995) Risk of relapse in childhood acute lymphoblastic leukaemia is related to RBC methotrexate and mercaptopurine metabolites during maintenance chemotherapy. Journal of Clinical Oncology, 13, 345-351.